Recap - Amicus Therapeutics’ (FOLD) positive phase 3 data on Wednesday meant a 50% return on our early August buy recommendation to PropThink Premium subscribers. Amicus reported results from … Continue Reading
Read NowInsights - Arrowhead Research (ARWR) raised as many questions as it answered this week when the company reported interim results from a mid-stage study of hepatitis B drug … Continue Reading
Read NowRecap - BOOM! Shares of Tekmira Pharmaceuticals (TKMR) climbed from $14 to $20 into Friday’s close after the FDA removed a clinical hold on the company’s Ebola therapeutic, essentially enabling its … Continue Reading
Read NowInsights - Tekmira Pharmaceuticals (TKMR) was the momentum stock of the week as the spread of Ebola continues in Guinea, Liberia and Sierra Leone, and two infected Americans … Continue Reading
Read NowInsights - The story of the week was Puma Biotechnology’s (PBYI) unexpected success in the phase 3 ExteNET trial, which sent the stock soaring 200% in after hours trading on Tuesday … Continue Reading
Read NowRecap - In the three trading sessions following the Fed’s semi-annual monetary policy report, in which the fed specifically called out small biotech equities as overvalued, the iShares … Continue Reading
Read NowRecap - Great news for longtime PropThink readers on Monday morning – BioDelivery Sciences (BDSI) announced positive results from the second of two phase 3 studies testing BEMA-Buprenorphine in chronic pain … Continue Reading
Read Now
